Pitavastatin + ezetimibe

Pitavastatin + ezetimibe has been studied in 2 papers since 2026: none in people yet, 2 reviews; 2 in the past year. No study of it in people or animals has been published yet. The newest paper, Nov 2, 2026: “Efficacy and Safety of Pitavastatin Plus Ezetimibe versus Pitavastatin Monotherapy in Adults with Hypercholesterolemia”.

Intervention

2 papers study it4 more mention it3 findingsUpdated

PubChemPubChemChEBIChEBI

3 new papers in 30 daysSee all 6 papers on pitavastatin + ezetimibe

At a glance

The findings reach people, from one lab or study. 2 independent labs in 2 countries; 2 trials, 2 about aging.

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 2 independent labs in 2 countries
  • 2 trials, 2 about aging
  • 2 of 2 trials sponsored by its developers

What did studies of pitavastatin + ezetimibe find?

3

Studies of pitavastatin + ezetimibe measured 3 outcomes: overall adverse events, LDL cholesterol and LDL.

Overall adverse events

no changein humans1RR 1.05

1 study
  1. Pitavastatin + ezetimibe showed no clear effect on overall adverse events in humans (hypercholesterolemia or dyslipidemia; compared with pitavastatin monotherapy) (RR 1.05; 95% CI 0.89–1.25).

    “The incidence of overall adverse events was similar between treatment groups (RR 1.05; 95% CI 0.89-1.25; I 2 = 0%).”

    Reviewhypercholesterolemia or dyslipidemia; compared with pitavastatin monotherapyn = 2,403

    Efficacy and Safety of Pitavastatin Plus Ezetimibe versus Pitavastatin Monotherapy in Adults with Hypercholesterolemia

    AHA Scientific Sessions 2026 abstract

LDL cholesterol

downin humans1

1 study
  1. Pitavastatin + ezetimibe decreases LDL cholesterol in humans (hypercholesterolemia or dyslipidemia; compared with pitavastatin monotherapy) (MD −22.54 mg/dL; 95% CI −25.47 to −19.61).

    “Compared with pitavastatin monotherapy, pitavastatin plus ezetimibe significantly reduced LDL-C levels”

    Reviewhypercholesterolemia or dyslipidemia; compared with pitavastatin monotherapyn = 2,403

    Efficacy and Safety of Pitavastatin Plus Ezetimibe versus Pitavastatin Monotherapy in Adults with Hypercholesterolemia

    AHA Scientific Sessions 2026 abstract

More on LDL cholesterol

LDL

downin humans1

1 study
  1. Pitavastatin + ezetimibe decreases LDL in humans (network meta-analysis of LDL reduction).

    “For LDL reduction, the combination of moderate-intensity pitavastatin and ezetimibe was the most effective”

    Reviewnetwork meta-analysis of LDL reductionmoderate-intensityn = 43,625

    Safety and efficacy of low-density lipoprotein-lowering drugs in the elderly: a network meta-analysis of randomized controlled trials

    Journal of geriatric cardiology : JGC

More on LDL

Has pitavastatin + ezetimibe been tested in people?

2 of 2 about aging

No study of it in people has been published yet.

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 2Sep 2026: 0Oct 2026: 0Nov 2026: 15 papers in 12 months